Please login to the form below
advanced breast cancer
This page shows the latest advanced breast cancer news and features for those working in and with pharma, biotech and healthcare.
Novartis considers filings for PI3K drug in breast cancer
Novartis has positive phase III results in hand for its PI3K inhibitor alpelisib in advanced breast cancer patients, which it hopes will be enough to file for regulatory approvals. ... Approximately 40% of HR+ advanced breast cancer patients have PIK3CA
Latest news
-
Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more
breast cancer (MBC), with the EMA also accepting the filing. ... In January, Lynparza became the first of the class to gain approval in breast cancer, with ovarian cancer being the primary focus for the competitors.
-
FDA backs earlier use of Lilly’s breast cancer drug Verzenio
negative metastatic breast cancer, ”said Joyce O'Shaughnessy, chair of the breast cancer research programme for Baylor University Medical Center, in a press release. ... This information will help inform treatment decisions for each patient, which can
-
AZ and Merck & Co get FDA breast cancer nod for Lynparza
AstraZeneca and Merck &Co have been awarded FDA approval for Lynparza in BRCA-positive advanced breast cancer - the first drug in the PARP inhibitor class to be approved outside ovarian cancer. ... The drug can also be used in hormone receptor-positive
-
Novartis bags new breakthrough status for Kisqali in breast cancer
The BTD is based on the results of the MONALEESA-7 trial, which involved pre-menopausal women with hormone-receptor positive, HER2-negative advanced breast cancer and was the first to ... If approved in younger women with advanced breast cancer, Kisqali
-
NICE set to reject wider use of Eisai’s Halaven
The UK health technology assessment agency says there is a lack of evidence that Halaven offers value for money in locally-advanced or secondary breast cancer in patients who have previously ... Advanced breast cancer patients are generally offered an
More from news
Approximately 1 fully matching, plus 145 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being
-
Digital disruption
Targeting advanced breast cancer the partners will combine real-world patient data and cognitive computing to ‘optimise cancer care and improve outcomes’. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.
-
Deal Watch August 2016
The lead product is talazoparib, a PARP inhibitor, bought from BioMarin in phase III for treatment of BRCA mutated advanced breast cancer. ... This would complement Pfizer's palbococlib, launched in the US in February 2015, to treat HR+/HER2 metastatic
-
Pharma deals during July 2014
Seragon's focus is in hormone dependent cancers and specifically the development of its Selective Estrogen Receptor Degrader (SERD) platform of oral, small molecule therapeutics for breast and other cancers. ... The lead SERD compound, ARN-810, is
-
Pharma deals during August 2013
To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... Palbociclib, which is the result of an early
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
FALCON trial of fulvestrant for advanced breast cancer
FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. ... In the interview, he explains that the study was designed to address the
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Account Manager
-
Negotiable
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Systematic Review Lead- London
-
Negotiable
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Associate Scientific Director
-
Salary TBC
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Account Director or Senior Account Director
-
Salary TBC
- Sudler London - Senior Medical Writer
-
Competitive
-
Sudler London - Account Director
-
Competitive
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
Subscribe to our email news alerts
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
